Hospital
Mymichigan Medical Center Gladwin
Mymichigan Medical Center Gladwin was paid $10.43M by Medicaid between Jan 2018 and Dec 2024, across 168 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoMYMICHIGAN MEDICAL CENTER GLADWIN
GLADWIN, MI 48624
GLADWIN, MI 48624
33aNPI1235248071assigned 08/29/2006
33bProvider typeCritical Access Hospital
28Total paid$10.43M
24GClaims331,140
24DCodes billed168
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#6 of 31
Median peer was paid$6.03M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JAMES, SARAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,748 | $1.14M | |
| 2019 | 46,926 | $1.10M | |
| 2020 | 40,085 | $1.28M | |
| 2021 | 49,336 | $1.74M | |
| 2022 | 49,913 | $1.81M | |
| 2023 | 51,256 | $1.74M | |
| 2024incomplete | 44,876 | $1.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 14,049 | 13,270 | $1.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 9,218 | 8,533 | $1.81M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 4,231 | 3,810 | $1.31M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.0% | 5,259 | 4,776 | $627K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 5,735 | 5,517 | $512K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.7% | 4,417 | 3,252 | $488K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 2,672 | 2,576 | $488K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 2,449 | 2,347 | $289K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 6,958 | 6,742 | $251K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 3,552 | 2,679 | $235K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.2% | 5,567 | 4,848 | $230K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 8,461 | 2,396 | $221K |
156 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 4,453 | $188K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 4,804 | $168K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,088 | $133K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 1,175 | $130K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 2,698 | $120K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 1,921 | $119K |
| 80061 | Lipid panel | <1% | 5,946 | $95K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 380 | $69K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,787 | $66K |
| 80053 | Comprehensive metabolic panel | <1% | 22,915 | $65K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,832 | $65K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 720 | $52K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,615 | $50K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 207 | $45K |
| 76830 | Ultrasound, transvaginal | <1% | 497 | $38K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,676 | $38K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,109 | $36K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,029 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,460 | $32K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,448 | $32K |
| 97161 | <1% | 412 | $29K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,890 | $28K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 390 | $27K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,061 | $24K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 442 | $24K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 156 | $23K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,185 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,176 | $19K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,281 | $18K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,630 | $16K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,139 | $15K |
| 87081 | <1% | 5,258 | $12K | |
| 94060 | <1% | 74 | $12K | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 852 | $12K |
| 86900 | <1% | 361 | $12K | |
| 71271 | <1% | 147 | $11K | |
| 84439 | <1% | 1,878 | $10K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,895 | $10K |
| 72100 | <1% | 252 | $9K | |
| 82607 | <1% | 981 | $8K | |
| 73630 | <1% | 1,056 | $8K | |
| 86803 | <1% | 871 | $8K | |
| 87186 | <1% | 1,975 | $8K | |
| 73030 | <1% | 609 | $8K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 333 | $7K |
| 87088 | <1% | 1,913 | $7K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 30 | $7K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 319 | $6K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 360 | $6K |
| 85027 | <1% | 1,427 | $5K | |
| 83880 | <1% | 1,398 | $5K | |
| 71250 | <1% | 78 | $5K | |
| 93971 | <1% | 79 | $5K | |
| 82728 | <1% | 543 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,885 | $5K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 49 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,889 | $5K |
| 81001 | <1% | 10,093 | $4K | |
| 87070 | <1% | 815 | $4K | |
| 87077 | <1% | 1,052 | $4K | |
| 83735 | <1% | 3,428 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 248 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 150 | $3K |
| 96367 | <1% | 69 | $3K | |
| 73610 | <1% | 526 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 32 | $3K |
| 83550 | <1% | 549 | $3K | |
| 80306 | <1% | 1,630 | $3K | |
| 86140 | <1% | 1,777 | $3K | |
| 73130 | <1% | 468 | $3K | |
| 93225 | <1% | 50 | $3K | |
| 82043 | <1% | 681 | $3K | |
| 83540 | <1% | 631 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 97 | $3K |
| 82746 | <1% | 274 | $3K | |
| 85610 | <1% | 6,240 | $2K | |
| 73564 | <1% | 207 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,766 | $2K |
| 87634 | <1% | 29 | $2K | |
| 82570 | <1% | 459 | $2K | |
| 87075 | <1% | 354 | $2K | |
| 87808 | <1% | 180 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 82 | $2K |
| 85652 | <1% | 1,186 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,659 | $1K |
| 74019 | <1% | 81 | $1K | |
| 83690 | <1% | 3,744 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 124 | $1K |
| 97162 | <1% | 26 | $1K | |
| 76801 | <1% | 12 | $980.64 | |
| 73110 | <1% | 101 | $761.03 | |
| 85730 | <1% | 1,095 | $733.96 | |
| 80076 | <1% | 109 | $573.06 | |
| 74018 | <1% | 41 | $569.77 | |
| 72131 | <1% | 15 | $556.45 | |
| 84702 | <1% | 93 | $536.06 | |
| 74022 | <1% | 443 | $513.30 | |
| 76642 | <1% | 13 | $494.80 | |
| 81025 | <1% | 2,935 | $448.79 | |
| 86038 | <1% | 59 | $429.50 | |
| 97012 | <1% | 60 | $356.44 | |
| 87276 | <1% | 3,514 | $346.68 | |
| 73502 | <1% | 27 | $342.36 | |
| 84153 | <1% | 28 | $293.01 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 12 | $274.53 |
| 83605 | <1% | 2,963 | $269.83 | |
| 73562 | <1% | 12 | $268.61 | |
| 87275 | <1% | 3,514 | $265.38 | |
| 93017 | <1% | 15 | $253.30 | |
| 87430 | <1% | 3,286 | $219.45 | |
| 72110 | <1% | 26 | $198.47 | |
| 85379 | <1% | 628 | $197.47 | |
| 87807 | <1% | 398 | $182.60 | |
| 87340 | <1% | 62 | $180.41 | |
| 84703 | <1% | 484 | $179.17 | |
| 84484 | <1% | 5,006 | $160.75 | |
| 87040 | <1% | 841 | $145.12 | |
| 86431 | <1% | 26 | $75.36 | |
| 86592 | <1% | 15 | $51.18 | |
| 82962 | <1% | 1,127 | $10.28 | |
| 93226 | <1% | 50 | $9.66 | |
| A9270 | Non-covered item or service | <1% | 1,298 | $0.38 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,525 | $0.10 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,248 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 890 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,229 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 172 | $0.00 |
| 94729 | 0% | 98 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 41 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 116 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 114 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 171 | $0.00 |
| 90715 | 0% | 73 | $0.00 | |
| 94726 | 0% | 49 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 39 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 20 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 714 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,507 | $0.00 |
| 96376 | 0% | 1,581 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 2,576 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,623 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 474 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 135 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,142 | $0.00 |
| 86901 | 0% | 361 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 160 | $0.00 |
| 86850 | 0% | 216 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 119 | $0.00 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 15 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 41 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 12 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 12 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 12 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 13 | $0.00 |
| 12001 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJAMES, SARAH (MANAGER, PROVIDER ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.